Drug updated on 11/13/2023

Dosage FormInjection (intravenous; 1,000 mg/40 mL (25 mg/mL))
Drug ClassHuman monoclonal antibodies that bind to Clostridium difficile toxin B
Ongoing and Completed StudiesClinicalTrials.gov


  • Indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at a high risk for CDI recurrence.

Product Monograph / Prescribing Information

Document TitleYearSource
Zinplava (bezlotoxumab) Prescribing Information.2016Merck & Co Inc., Whitehouse Station, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines